InsiderTrades

Krause Kevin Michael

SEC CIK 1916925 · EDGAR

Buying vs selling by month open-market trades, last 33 months, ANTX
BoughtSold

Companies

TickerCompanyTitleHoldingBoughtSoldTradesFirstLast
ANTXAN2 Therapeutics, Inc.Chief Strategy Off 31.9K — $201.3K 62024-01-022024-03-15

Most active insiders at ANTX, 12 months

#InsiderTitleBoughtSold
1 Readnour Robin ShaneDir —$316.7K
2 Eizen Joshua MSee Remarks —$52.9K
3 FitzPatrick Margaret MDir $11.6K—
4 Chanda SanjayChief Development Off —$9,311
5 Day LucyCFO —$8,862
6 Prior Stephen DavidChief Strategy Off —$7,363
7 Williams Sarah JoannePrincipal Accounting Off —$3,025
8 Trenor Cameron C. IIIChief Medical Off ——
9 Marks Gilbert LynnDir ——
10 Martin Patricia A.Dir ——

Krause Kevin Michael made no open-market trades at ANTX in the last 12 months.

Transactions 6

Type
Reset
X Filed Traded Ticker Company Insider Title Type Price Qty Owned ΔOwn Value
A 2024-03-29 2024-03-15 ANTX AN2 Therapeutics, Inc. Krause Kevin Michael Chief Strategy Off A - Grant $0.00 +30.0K 31.9K +1,567% $0
D 2024-03-18 2024-03-15 ANTX AN2 Therapeutics, Inc. Krause Kevin Michael Chief Strategy Off A - Grant $0.00 +30.0K 31.9K +1,567% $0
DMT 2024-01-11 2024-01-09 ANTX AN2 Therapeutics, Inc. Krause Kevin Michael Chief Strategy Off M - OptEx $4.59 +7,417 9,331 +388% +$34.0K
DT 2024-01-11 2024-01-09 ANTX AN2 Therapeutics, Inc. Krause Kevin Michael Chief Strategy Off S - Sale+OE $20.14 -7,417 1,914 -79% -$149.4K
DT 2024-01-04 2024-01-02 ANTX AN2 Therapeutics, Inc. Krause Kevin Michael Chief Strategy Off M - OptEx $0.42 +2,583 4,497 +135% +$1,085
DT 2024-01-04 2024-01-02 ANTX AN2 Therapeutics, Inc. Krause Kevin Michael Chief Strategy Off S - Sale+OE $20.12 -2,583 1,914 -57% -$52.0K

Purchase Sale Sale after option exercise All abbreviations